You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍隨A股同業下跌 藥明生物(02269.HK)及季績後石藥(01093.HK)曾挫6%-8%
內地醫藥生物板塊逆市(滬指及深成半日反覆續彈0.7%-0.9%)跌0.8%,其中藥明康德A股(603259.SH)低見87.13元人民幣,半日收88.69元人民幣,跌2.9%;康辰藥業(603590.SH)及歐林生物(688319.SH)挫逾7%及8%,半日收27.61元及22.13元人民幣。 本港醫藥股今天也跑輸大市,尤其是藍籌石藥(01093.HK)首季少賺4.6%至14.05億人民幣,野村及瑞信績後削其目標價至11.64元及12元。該股今早曾挫逾8%失守52周低位7.28元,最低見7.2元,為2020年底以來最低,現報7.42元,回吐5.4%。 疫苗股三葉草生物(02197.HK)三連跌兼失守20天線(4.18元),最低見3.93元,現報4.05元,續跌5.6%。金斯瑞生物(01548.HK)三連跌,最低見19.62元,現報20.05元,跌2.9%。騰盛博藥(02137.HK)低見7.85元,現報7.99元,跌2.6%。 藥明生物(02269.HK)反彈受制10天及20天線,今早曾挫近6%低見50.15元,現報51.3元,回吐3.8%。藥明康德(02359.HK)四連跌,最低見85.6元,創約兩個半月低喘定,現報87.85元,續跌1%。 藍籌中生製藥(01177.HK)回吐2.3%報4.17元。復星醫藥(02196.HK)三連跌,最低見30.85元,現報31.6元,續跌1.4%。 四環醫藥(00460.HK)今天除淨末期及特別股息共13.3仙,股價考驗10天及20天線(1.06元),最低見1.06元,現報1.07元,回吐3.3%。 然而,疫苗股開拓藥物(09939.HK)及擬向特定對象發售最多3億人民幣A股的康希諾(06185.HK)逆同業反覆續彈1.3%及0.9%,現報22.8元及70.55元。此外,三生製藥(01530.HK)及信達生物(01801.hk)也反覆升1.1%及0.9%,分別報5.46元及21.35元。 恆指今早在金融股等支撐高開100點或0.5%報20,272欠承接,在新經濟、內需及醫藥股等主導,掉頭曾倒跌280點或1.4%報19,890獲支持,逐步收復失地,現報20,126,僅續跌44點或0.2%,成交額501億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account